
1. Arq Neuropsiquiatr. 2021 Nov;79(11):1049-1061. doi:
10.1590/0004-282X-ANP-2021-0162.

Recommendations by the Scientific Department of Neuroimmunology of the Brazilian 
Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and
Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on
vaccination in general and specifically against SARS-CoV-2 for patients with
demyelinating diseases of the central nervous system.

Becker J(1), Ferreira LC(2)(3), Damasceno A(4), Bichuetti DB(5), Christo PP(6),
Callegaro D(7), Peixoto MAL(6), Sousa NAC(8), Almeida SM(9), Adoni T(10),
Santiago-Amaral J(6), Junqueira T(11), Pereira SLA(7), Gomes ABAGR(7), Pitombeira
M(12), Paolilo RB(7), Grzesiuk AK(13), Piccolo AC(14), D Almeida JAC(12), Gomes
Neto AP(15), Oliveira ACP(16), Oliveira BS(17), Tauil CB(18), Vasconcelos CF(19),
Kaimen-Maciel D(20), Varela D(21), Diniz DS(22), Oliveira EML(5), Malfetano
FR(23), Borges FE(24), Figueira FFA(25), Gondim FAA(26), Passos GRD(1), Silva
GD(7), Olival GSD(27)(28), Santos GACD(23)(29), Ruocco HH(29)(30), Sato HK(31),
Soares Neto HR(32), Cortoni Calia L(33), Gonçalves MVM(34), Vecino MCA(35),
Pimentel MLV(36), Ribeiro MC(37), Boaventura M(7), Parolin MKF(38), Melo RBS(15),
Lázaro R(39), Thomaz RB(40), Kleinpaul R(6), Dias RM(41), Gomes S(42), Lucatto
SA(43), Alves-Leon SV(44), Fukuda T(45), Ribeiro TAGJ(22), Winckler TCD(38),
Fragoso YD(46), Nascimento OJMD(23)(29), Ferreira MLB(47), Mendes MF(28), Brum
DG(48), Glehn FV(4)(49).

Author information: 
(1)Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS,
Brazil.
(2)Universidade Federal de Sergipe, Aracaju SE, Brazil.
(3)Universidade Tiradentes, Aracaju SE, Brazil.
(4)Universidade de Campinas, Faculdade de Ciências Médicas, Campinas SP, Brazil.
(5)Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, 
Brazil.
(6)Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil.
(7)Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São
Paulo SP, Brazil.
(8)Universidade Federal do Amazonas, Manaus AM, Brazil.
(9)Universidade Federal do Paraná, Curitiba PR, Brazil.
(10)Hospital Sírio Libanês, São Paulo SP, Brazil.
(11)Escola Bahiana de Medicina e Saúde Pública, Salvador BA, Brazil.
(12)Hospital Geral de Fortaleza, Fortaleza CE, Brazil.
(13)Clínica Nossa Senhora das Graças, Cuiabá MS, Brazil.
(14)Hospital Santa Marcelina, São Paulo SP, Brazil.
(15)Santa Casa, Belo Horizonte MG, Brazil.
(16)Instituto de Infectologia Emílio Ribas, São Paulo SP, Brazil.
(17)Fundação Centro Integrado de Apoio ao Portador de Deficiência, João Pessoa
PB, Brazil.
(18)Secretaria de Estado da Saúde, Brasília DF, Brazil.
(19)Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil.
(20)Santa Casa, Londrina PR, Brazil.
(21)Hospital de Clínicas de Passo Fundo, Passo Fundo RS, Brazil.
(22)Universidade Federal de Goiás, Goiânia GO, Brazil.
(23)Universidade Estácio de Sá, Rio de Janeiro RJ, Brazil.
(24)Private Service, Goiânia GO, Brazil.
(25)Hospital São Francisco na Providência de Deus, Rio de Janeiro RJ, Brazil.
(26)Universidade Federal do Ceará, Fortaleza CE, Brazil.
(27)Associação Brasileira de Esclerose Múltipla, São Paulo SP, Brazil.
(28)Santa Casa, São Paulo SP, Brazil.
(29)Universidade Federal Fluminense, Niterói RJ, Brazil.
(30)Pontifícia Universidade Católica, Campina SP, Brazil.
(31)Instituto de Neurologia de Curitiba, Curitiba PR, Brazil.
(32)IAMSPE, São Paulo SP, Brazil.
(33)Private Service, São Paulo SP, Brazil.
(34)Universidade da Região de Joinville, Joinville SC, Brazil.
(35)Hospital Moinhos de Vento, Porto Alegre RS, Brazil.
(36)Santa Casa, Rio de Janeiro RJ, Brazil.
(37)Universidade Federal Ciências da Saúde de Porto Alegre, Porto Alegre RS,
Brazil.
(38)Private Service, Curitiba PR, Brazil.
(39)Faculdade de Medicina de Jundiaí, Jundiaí SP, Brazil.
(40)Hospital Israelita Albert Einstein, São Paulo SP, Brazil.
(41)Hospital de Base do Distrito Federal, Brasília DF, Brazil.
(42)Hospital Beneficiência Portuguesa, São Paulo SP, Brazil.
(43)Hospital Regional de Vilhena, Vilhena RO, Brazil.
(44)Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro RJ, Brazil.
(45)Hospital Universitário Prof. Edgar Santos, Salvador BA, Brazil.
(46)Universidade Metropolitana de Santos, Santos SP, Brazil.
(47)Hospital da Restauração, Recife PE, Brazil.
(48)Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, Botucatu
SP, Brazil.
(49)Universidade de Brasília, Faculdade de Medicina, Brasília DF, Brazil.

The Scientific Department of Neuroimmunology of the Brazilian Academy of
Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in
Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide
recommendations in this document for vaccination of the population with
demyelinating diseases of the central nervous system (CNS) against infections in 
general and against the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current 
situation in view of the spread of COVID-19 in our country. Therefore, reference 
guides on vaccination for clinicians, patients, and public health authorities are
particularly important to prevent some infectious diseases. The DCNI/ABN and
BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and
NMOSD) be continually monitored for updates to their vaccination schedule,
especially at the beginning or before a change in treatment with a disease
modifying drug (DMD). It is also important to note that vaccines are safe, and
physicians should encourage their use in all patients. Clearly, special care
should be taken when live attenuated viruses are involved. Finally, it is
important for physicians to verify which DMD the patient is receiving and when
the last dose was taken, as each drug may affect the induction of immune response
differently.

DOI: 10.1590/0004-282X-ANP-2021-0162 
PMID: 34816999 

